KL-590586 (A400/EP0031): A Comprehensive Profile of a Next-Generation Selective RET Inhibitor for the Treatment of RET-Altered Malignancies

Executive Summary

KL-590586, also designated A400/EP0031, is an orally bioavailable, next-generation selective rearranged during transfection (RET) kinase inhibitor under development by Sichuan Kelun-Biotech and its global partner, Ellipses Pharma. This investigational agent is engineered to address the primary clinical limitations of first-generation selective RET inhibitors (SRIs), namely acquired resistance and the progression of central nervous system (CNS) metastases. Clinical data from the foundational Phase I/II KL400-I/II-01 study have demonstrated robust and durable anti-tumor activity across a range of RET-altered solid tumors.

In treatment-naïve patients with RET fusion-positive non-small cell lung cancer (NSCLC), KL-590586 has achieved an objective response rate (ORR) as high as 80.8%, positioning it as a highly potent first-line therapeutic option.[1] The agent has also shown significant efficacy in heavily pre-treated NSCLC patients, with an ORR of approximately 63% to 70%, and has produced meaningful clinical responses in patients who have progressed on prior first-generation SRI therapy, confirming its ability to overcome established resistance mechanisms.[3] Furthermore, KL-590586 exhibits compelling intracranial efficacy, with a CNS disease control rate of 100% and observations of complete tumor shrinkage in brain lesions, addressing a critical unmet need in this patient population.[3]

The safety profile of KL-590586 appears favorable and distinct from that of current standards of care. The incidence of toxicities commonly associated with first-generation SRIs, such as hypertension, QT interval prolongation, and significant hematological events, is notably low.[3] The most frequent treatment-related adverse events are manageable Grade 1-2 elevations in liver enzymes, creatinine, and bilirubin, along with constipation and headache, with low rates of dose reduction or discontinuation.[3]

The compound's development is proceeding under an accelerated regulatory framework, having received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA).[1] A significant milestone was reached in September 2025 with the acceptance of a New Drug Application (NDA) by China's National Medical Products Administration (NMPA) for RET fusion-positive NSCLC.[6] Based on its differentiated profile of potent systemic and intracranial efficacy, activity against resistance mutations, and a manageable safety profile, KL-590586 is strongly positioned to become a best-in-class agent and a new standard of care for patients with RET-altered malignancies.

The Therapeutic Landscape of RET-Altered Cancers

The clinical and scientific context for the development of KL-590586 is rooted in the evolution of precision oncology for cancers driven by alterations in the RET proto-oncogene. The RET gene encodes a receptor tyrosine kinase critical for cell growth, differentiation, and survival. Specific genetic alterations, including gene fusions and activating point mutations, can transform RET into a potent oncogenic driver.[8] These alterations are found across a spectrum of malignancies, occurring in approximately 1-2% of non-small cell lung cancers (NSCLC), 10-20% of papillary thyroid cancers, and the majority of sporadic and hereditary medullary thyroid cancers (MTC).[7] RET alterations are also identified in other solid tumors, including colorectal and pancreatic cancers, establishing a clear, molecularly defined patient population for targeted therapies.[10]

Historically, patients with RET-altered cancers were treated with conventional cytotoxic chemotherapy and, more recently, immune checkpoint inhibitors. However, these modalities have demonstrated limited efficacy in this patient subset, leading to poor prognoses and highlighting a significant unmet medical need.[5] The first major therapeutic advance came with repurposed multi-kinase inhibitors (MKIs) that had incidental activity against RET. While providing some benefit, the clinical utility of these agents was constrained by modest efficacy and significant off-target toxicities, resulting from the inhibition of other kinases like VEGFR2.[5]

The therapeutic landscape was transformed in 2020 with the approval of the first-generation, highly selective RET inhibitors (SRIs) selpercatinib (Retevmo) and pralsetinib (Gavreto). These agents demonstrated impressive and durable responses in single-arm pivotal trials, such as LIBRETTO-001 for selpercatinib and ARROW for pralsetinib, and rapidly became the standard of care for newly diagnosed and previously treated patients with RET-altered NSCLC and thyroid cancers.[12] However, widespread clinical use has revealed two critical limitations that define the next frontier of unmet needs.

First is the inevitable emergence of acquired resistance. A primary mechanism of treatment failure is the development of on-target secondary mutations within the RET kinase domain. Of particular importance are solvent front mutations, such as those at the G810 residue (e.g., G810R, G810S, G810C), which sterically hinder the binding of first-generation inhibitors and restore kinase activity, leading to clinical progression.[2] This creates a well-defined patient population with limited effective treatment options following initial success with selpercatinib or pralsetinib.

Second is the challenge of central nervous system (CNS) disease. The brain is a common site of metastasis for NSCLC and other cancers, and it functions as a sanctuary site where drug penetration may be limited by the blood-brain barrier. While first-generation SRIs possess some CNS activity, intracranial progression remains a significant cause of morbidity and mortality, underscoring the need for next-generation agents with superior brain penetration and more profound, durable intracranial efficacy.[3] The clinical landscape has therefore matured from a broad need for any effective RET-targeted therapy to a more sophisticated set of requirements: a therapy that not only provides high initial response rates but also overcomes known resistance mechanisms and effectively controls disease in the CNS. The development of KL-590586 is a direct response to these specific, second-generation unmet clinical needs.

KL-590586 - Profile of a Novel Kinase Inhibitor

KL-590586 is an investigational, orally bioavailable small molecule designed as a potent and highly selective inhibitor of the RET receptor tyrosine kinase.[1] The compound is known by several designations that reflect its developmental history and corporate stewardship.

KL590586 is the internal research code used by its originating developer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..[6] The codes

A400 and EP0031 are used in the context of its global clinical development program, with A400 often used jointly and EP0031 used specifically by its international partner.[6]

The development and commercialization of KL-590586 are governed by a strategic partnership that leverages regional expertise to accelerate its global trajectory. The drug was discovered and is being developed in China by Sichuan Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, which has a growing portfolio of innovative oncology assets, including a proprietary antibody-drug conjugate (ADC) platform known as OptiDC™.[7] This positions Kelun-Biotech as a key player in China's rapidly advancing biopharmaceutical sector.

To facilitate global development, Kelun-Biotech entered into a licensing agreement in March 2021 with Ellipses Pharma Limited, a UK-based company focused on accelerating the development of promising cancer therapies.[7] Under the terms of the agreement, Ellipses Pharma holds the exclusive license to develop, manufacture, and commercialize the agent—under the designation EP0031—in territories outside of Greater China, including the United States and Europe.[10] Kelun-Biotech retains rights for Greater China and select Asia-Pacific countries, such as South Korea, Singapore, and Malaysia.[11] This dual-company, dual-hemisphere strategy enables the simultaneous execution of clinical trials and regulatory interactions in the world's largest pharmaceutical markets. By running parallel development programs, the partners can generate a comprehensive global data package more efficiently than a traditional sequential approach, potentially reducing the time to market and accelerating patient access worldwide.

Characteristic	Details
Primary Name	KL-590586
Alternative Designations	A400, EP0031
Drug Class	Small Molecule, Selective RET Tyrosine Kinase Inhibitor
Administration Route	Oral (Capsules) 19
Originating Developer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Global Partner (ex-China)	Ellipses Pharma Limited
Table 1: Key Characteristics of KL-590586

Preclinical Rationale and Pharmacological Profile

The development of KL-590586 is founded on a rational drug design strategy aimed at creating a molecule that specifically overcomes the known liabilities of first-generation SRIs. Its preclinical profile was engineered to deliver superior selectivity, potent activity against resistance mutations, and enhanced CNS penetration.

Mechanism of Action

As a selective RET kinase inhibitor, KL-590586 exerts its antineoplastic activity by binding to the ATP-binding pocket of the RET protein, including its mutated and fusion-product forms.[16] In RET-altered cancers, these aberrant proteins are constitutively active, leading to uncontrolled activation of downstream signaling cascades, such as the RAS/MAPK and PI3K/AKT pathways, which drive cellular proliferation and survival. By selectively binding to and inhibiting the kinase activity of RET, KL-590586 effectively shuts down this oncogenic signaling, resulting in the inhibition of tumor cell growth and the induction of apoptosis in susceptible cancer cells.[16]

Preclinical Evidence of a Differentiated Profile

The preclinical data package for KL-590586 provides a compelling, point-by-point scientific basis for its potential clinical superiority. The molecule was systematically optimized to address the key molecular failures of its predecessors.

• High Kinase Selectivity: A critical aspect of the design was to achieve high selectivity for RET over other kinases, particularly those implicated in the off-target toxicities of earlier inhibitors. Preclinical enzymatic assays demonstrated that KL-590586 is 93-fold more selective for RET than for VEGFR2, 10-fold more selective than for JAK1, and 22-fold more selective than for JAK2.[6] Inhibition of VEGFR2 is associated with toxicities such as hypertension, while JAK inhibition can lead to myelosuppression. This high degree of selectivity provides a strong pharmacological rationale for the improved safety profile observed in clinical trials, suggesting a wider therapeutic window.
• Potency Against Acquired Resistance Mutations: A primary design objective was to maintain potent inhibition against RET proteins harboring acquired resistance mutations. KL-590586 demonstrated greater potency against both common RET alterations and key resistance mutations compared to first-generation SRIs.[2] This was validated in vivo, where KL-590586 showed greater anti-tumor efficacy than first-generation agents in a patient-derived xenograft model expressing the G810R solvent front mutation.[6] This finding is not coincidental; it is direct evidence that the molecule was engineered to effectively bind to the kinase domain despite the steric changes imposed by this class of mutations, positioning it as a viable therapy after first-generation SRI failure.
• Superior Brain Penetration: Recognizing the clinical challenge of CNS metastases, KL-590586 was optimized for blood-brain barrier penetration. Animal models confirmed its ability to cross this barrier effectively.[11] In a direct preclinical test of this property, an intracranial tumor xenograft model, KL-590586 led to superior tumor exposure and improved survival compared to first-generation SRIs.[6] This preclinical evidence was a crucial predictor of the robust intracranial activity later confirmed in human clinical trials and represents a significant potential advantage for patients with or at risk of developing brain metastases.

Clinical Development and Trial Analysis

The clinical development program for KL-590586 is being executed through a coordinated global strategy, with parallel studies designed to rapidly generate robust data for regulatory submissions in major markets.

Overview of Clinical Program

The cornerstone of the clinical evidence for KL-590586 is the KL400-I/II-01 study (NCT05265091), a Phase I/II trial conducted in China and sponsored by Kelun-Biotech's research institute.[3] This study was designed with a Phase I component for dose-escalation and determination of the recommended Phase II dose (RP2D), followed by a Phase II component with expansion cohorts to evaluate efficacy and safety in specific patient populations.[3] The dose-escalation phase utilized a Bayesian Optimal Interval design and evaluated once-daily (QD) oral doses ranging from 10 mg to 120 mg.[3]

In parallel, a global Phase I/II trial, identified as the EP0031 study (NCT05443126), is being conducted by Ellipses Pharma.[21] This study, which received IND clearance from the U.S. FDA in June 2022, is active and enrolling patients in the United States, United Kingdom, Europe, and the United Arab Emirates.[1] This global trial leverages the findings from the KL400-I/II-01 study and is designed to confirm the safety and efficacy of KL-590586 in a broader international patient population, paving the way for regulatory submissions to the FDA, EMA, and other health authorities.

Pharmacokinetic Profile

Data from the Phase I portion of the KL400-I/II-01 study provided key insights into the human pharmacokinetics (PK) of KL-590586. The drug exhibited predictable, dose-dependent increases in plasma exposure across the dose levels tested.[3] A key finding was the drug's long mean half-life, which was determined to be in the range of 34.1 to 99.8 hours.[3] This favorable PK profile strongly supports a convenient once-daily oral dosing regimen, which can enhance patient adherence compared to twice-daily schedules. Clinical responses were observed at dose levels of 40 mg and higher, informing the selection of doses for the expansion phase of the study.[3]

In-Depth Analysis of Clinical Efficacy

The clinical efficacy of KL-590586 has been demonstrated across multiple patient populations in the KL400-I/II-01 study, establishing its potential as a highly active agent for RET-altered malignancies. The data package is strategically comprehensive, providing evidence for its utility in the first-line setting, in previously treated patients, in those who have developed resistance to prior SRIs, and in the difficult-to-treat setting of CNS metastases.

Efficacy in RET Fusion-Positive NSCLC

Non-small cell lung cancer represents a primary indication for KL-590586, and the results in this population have been particularly strong.

• Treatment-Naïve Patients: In patients with advanced RET fusion-positive NSCLC who had not received prior systemic therapy, KL-590586 demonstrated exceptional anti-tumor activity. An early analysis reported an ORR of 76% (19 of 25 patients), which included one complete response (CR).[3] A subsequent data cut from a larger cohort of 26 patients showed an even higher ORR of 80.8%.[1] The disease control rate (DCR), representing the proportion of patients achieving either a response or stable disease, was consistently high at 92% to over 96%.[2] These response rates are at the upper end of, or potentially superior to, those reported for first-generation SRIs, positioning KL-590586 as a formidable first-line treatment option.
• Previously Treated Patients: The agent also showed robust efficacy in a heavily pre-treated patient population, many of whom had received multiple lines of therapy including chemotherapy and immunotherapy. In this setting, the ORR was 63% (20 of 32 patients) with a DCR of 91% in one analysis.[3] A later report on 33 patients indicated an ORR of 69.7%.[1] Critically, responses were observed to be durable, with the median duration of response (DoR) not reached at the time of these analyses, suggesting sustained clinical benefit.

Efficacy in RET-Mutant Medullary Thyroid Cancer (MTC)

In patients with advanced RET-mutant MTC, KL-590586 also demonstrated profound and durable clinical activity. In a cohort of 27 patients, which included both treatment-naïve individuals and those previously treated with MKIs, the confirmed ORR (cORR) was 63.0% (17 of 27 patients), and the DCR was 100%.[22] The durability of these responses was a standout feature; with a median follow-up of 19.0 months, the median DoR had not been reached, and the estimated 24-month progression-free survival (PFS) rate was an impressive 77.8%.[23]

Activity Against Acquired Resistance and in the CNS

Two of the most significant findings from the clinical program are the drug's ability to overcome acquired resistance and its potent intracranial activity.

• Overcoming Resistance to First-Generation SRIs: The KL400-I/II-01 study included a cohort of nine patients whose disease had progressed on a prior first-generation SRI. In this critical population, KL-590586 induced tumor shrinkage in seven patients. This included three patients who achieved a confirmed partial response (PR) and four who achieved stable disease (SD).[3] This provides the first clinical proof-of-concept that KL-590586 is active against the mechanisms of resistance that limit the effectiveness of the current standard of care.
• Intracranial Efficacy: The preclinical promise of superior brain penetration translated directly into compelling clinical results. In a cohort of patients with baseline brain metastases who had not undergone prior brain radiotherapy, KL-590586 demonstrated profound intracranial activity. Among five patients with measurable intracranial lesions, four experienced significant tumor shrinkage of 100%, 100%, 80%, and 47%.[3] In a separate report, 100% tumor shrinkage in the brain was noted in three patients.[6] The overall CNS DCR was 100%, indicating that all patients with brain metastases experienced at least stabilization of their intracranial disease, a remarkable outcome for this challenging clinical scenario.[3]

Patient Cohort	N	Objective Response Rate (ORR)	Disease Control Rate (DCR)	Key Findings & Citations
Treatment-Naïve RET+ NSCLC	26	80.8%	>96%	High first-line activity; durable responses. 1
Previously Treated RET+ NSCLC	33	69.7%	>90%	Robust activity in a heavily pre-treated population. 1
Prior 1st-Gen SRI Treated	9	33% (3 PRs)	78% (3 PRs + 4 SDs)	Clinical proof-of-concept for overcoming acquired resistance. 3
RET-Mutant MTC	27	63.0%	100%	Highly durable responses; 24-month PFS rate of 77.8%. 22
Patients with Brain Metastases	5 (measurable)	80% (4/5)	100%	Profound intracranial activity, including complete responses. 3
Table 2: Summary of Efficacy Results from the KL400-I/II-01 Study

Comprehensive Safety and Tolerability Profile

A detailed analysis of the safety data from the KL400-I/II-01 study reveals a manageable and differentiated tolerability profile for KL-590586, which may represent a significant advantage over existing RET inhibitors.

In the Phase I study population of 87 patients treated across all dose levels, treatment-related adverse events (TRAEs) of any grade were reported in 93.1% of patients.[3] This high incidence is expected for an active targeted oncology agent administered chronically. Critically, the vast majority of these events—74.7%—were low-grade (Grade 1 or 2), generally reversible, and manageable with standard supportive care.[3]

The most frequently observed TRAEs were primarily laboratory abnormalities and mild clinical symptoms. As detailed in Table 3, these included increases in liver transaminases (AST and ALT), increases in creatinine and bilirubin, constipation, and headache.[3] Severe (Grade ≥3) TRAEs were uncommon, occurring in 24.1% of patients. The most frequent Grade ≥3 events were elevations in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), and ileus, each occurring in just 2.3% of patients.[3] The manageable nature of the side effect profile is further underscored by the low rates of dose modification; TRAEs led to dose reduction in only 4.6% of patients and permanent treatment discontinuation in 6.9%.[3]

The most strategically important aspect of the safety profile is its divergence from the known toxicities of first-generation SRIs. Adverse events that often require close monitoring and can be dose-limiting for selpercatinib and pralsetinib were rare and low-grade with KL-590586. Specifically, hypertension, QT interval prolongation, platelet decrease (thrombocytopenia), and lymphocyte decrease (lymphopenia) were each reported in less than 5% of patients.[3] This clinical safety data provides strong validation for the preclinical hypothesis that the high selectivity of KL-590586 for the RET kinase over other kinases like VEGFR2 and JAKs would translate into a more favorable and tolerable safety profile. This "cleaner" profile is not merely a secondary benefit; it is a primary strategic asset. It could expand the eligible patient population to include those with pre-existing comorbidities (e.g., cardiovascular conditions) who might be poor candidates for first-generation agents. Furthermore, a superior safety profile is a critical enabler for future development in combination with other anti-cancer agents, such as chemotherapy or other targeted therapies, where overlapping toxicities can be a major obstacle.

Treatment-Related Adverse Event	Any Grade Incidence (%)	Grade ≥3 Incidence (%)
AST Increase	50.6%	Not specified (>2%)
ALT Increase	48.3%	Not specified (>2%)
Creatinine Increase	33.3%	Not specified (>2%)
Bilirubin Increase	32.2%	Not specified (>2%)
Constipation	32.2%	Not specified (>2%)
Headache	31.0%	Not specified (>2%)
ALP Increase	Not specified	2.3%
GGT Increase	Not specified	2.3%
Ileus	Not specified	2.3%
Hypertension	<5%	Low-grade
QT Interval Prolongation	<5%	Low-grade
Platelets Decrease	<5%	Low-grade
Lymphocytes Decrease	<5%	Low-grade
Table 3: Profile of Treatment-Related Adverse Events (from KL400-I/II-01, N=87) 3

Regulatory and Commercialization Strategy

The development of KL-590586 is proceeding along an accelerated and strategically coordinated global regulatory path, marked by key designations and submissions that underscore its clinical promise and potential to address unmet medical needs.

United States (FDA)

The regulatory journey in the United States, spearheaded by Ellipses Pharma, has been characterized by a sequence of positive interactions with the Food and Drug Administration (FDA) that facilitate an expedited development timeline.

• Investigational New Drug (IND) Approval (June 2022): The FDA cleared the IND application for A400/EP0031, permitting the initiation of clinical trials in the U.S. and marking the official start of its ex-China clinical program.[1]
• Orphan Drug Designation (ODD) (November 2023): The FDA granted ODD to A400/EP0031 for the treatment of RET fusion-positive solid tumors.[1] This designation is for drugs treating rare diseases (affecting fewer than 200,000 people in the U.S.) and provides significant incentives, including potential for seven years of market exclusivity upon approval, tax credits for clinical trials, and waiver of prescription drug user fees.[11]
• Fast Track Designation (March 2024): The FDA granted Fast Track designation for the treatment of RET fusion-positive NSCLC.[1] This is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent meetings with the FDA and eligibility for Accelerated Approval and Priority Review, if relevant criteria are met.[21]
• Phase 2 Clearance (April 2024): Following a review of Phase 1 data, the FDA cleared the program to advance into Phase 2 clinical development in the U.S..[1]

This combination of ODD and Fast Track designations serves as strong external validation from the FDA, indicating that the agency has reviewed the preclinical and early clinical data and recognizes the agent's potential to provide a significant therapeutic advance. This de-risks the development program and signals a collaborative and expedited path toward a potential U.S. marketing application.

China (NMPA)

In China, development led by Kelun-Biotech has progressed at a remarkable pace, culminating in a major regulatory filing.

• New Drug Application (NDA) Acceptance (September 2025): China's National Medical Products Administration (NMPA) accepted the NDA for A400/EP0031 for the treatment of adult patients with RET fusion-positive, locally advanced or metastatic NSCLC.[6] This acceptance is a pivotal step, moving the drug from the investigational stage to formal regulatory review for marketing approval in China. The submission was based on the positive pivotal Phase 2 results from the KL400-I/II-01 study.[7]

Europe and Other Regions

The global development strategy extends beyond the U.S. and China. The global Phase I/II trial (NCT05443126) is actively enrolling patients in the United Kingdom, Europe, and the United Arab Emirates.[7] This ensures that data are being generated to support future marketing applications with the European Medicines Agency (EMA) and other international health authorities, laying the groundwork for broad global access upon approval.

Strategic Positioning and Future Outlook

KL-590586 is strategically positioned not merely as an alternative to existing RET inhibitors, but as a potential best-in-class agent designed to supersede the current standard of care across multiple clinical scenarios. Its future outlook is shaped by its competitive advantages in efficacy, resistance, CNS activity, and safety.

Competitive Landscape Analysis

A direct comparison with the first-generation SRIs, selpercatinib and pralsetinib, highlights the differentiated profile of KL-590586.

• Efficacy: While selpercatinib and pralsetinib set a high bar with ORRs in the range of 60-85% in treatment-naïve NSCLC, the reported ORR of over 80% for KL-590586 in the same setting suggests it is at least as effective, and potentially superior.[1]
• Resistance Profile: This is the most significant point of differentiation. KL-590586 has demonstrated clinical activity in patients who have progressed on first-generation SRIs, directly addressing the primary unmet need of acquired resistance.[3] In contrast, selpercatinib and pralsetinib are known to be vulnerable to solvent front and other mutations that limit their long-term durability.[15]
• CNS Activity: The compelling preclinical and clinical data showing profound intracranial responses, including complete disappearance of brain lesions, suggest that KL-590586 may offer best-in-class CNS disease control.[3] This is a critical advantage, as CNS progression is a major clinical challenge.
• Safety and Tolerability: The favorable safety profile of KL-590586, with low rates of hypertension, QTc prolongation, and hematological toxicities, contrasts with the known safety profiles of its competitors and could make it the preferred agent, particularly for patients with comorbidities or those at risk for such side effects.[3]

This multi-faceted profile allows KL-590586 to be positioned to capture market share across the entire patient journey. It can compete to be the first choice in the first-line setting based on high efficacy and superior safety; the definitive option for patients with CNS involvement; and the essential go-to therapy in the second-line setting after resistance to a first-generation SRI develops.

Feature	KL-590586 (A400/EP0031)	Selpercatinib (Retevmo)	Pralsetinib (Gavreto)
Efficacy (1L NSCLC ORR)	~80.8% 1	~85% 8	~70-73% 8
Activity vs. G810 Resistance	Demonstrated Clinical Activity 3	Known Mechanism of Resistance 15	Known Mechanism of Resistance 15
Intracranial Efficacy	High ORR (80%); 100% DCR 3	Reported CNS Activity	Reported CNS Activity
Key Grade ≥3 Toxicities	LFT elevations, Ileus 3	Hypertension, LFT elevations, Diarrhea, Lymphopenia 13	Neutropenia, Anemia, Hypertension, Pneumonitis 8
Dosing Schedule	Once Daily 3	Twice Daily 25	Once Daily 25
Table 4: Comparative Analysis: KL-590586 vs. First-Generation RET Inhibitors

Future Clinical Development and Outlook

The development program for KL-590586 is advancing rapidly. The Phase 2 portions of the KL400-I/II-01 and NCT05443126 trials are ongoing and will serve as the basis for regulatory submissions in China and globally, respectively.[7] Key future catalysts will include the reporting of top-line results from these pivotal studies and subsequent regulatory decisions from the NMPA and FDA.

Expansion of the program into other RET-altered solid tumors is a logical next step, building on the early signals of tumor-agnostic activity and the Orphan Drug Designation that covers all RET fusion-positive solid tumors.[7] The drug's favorable safety profile also creates significant opportunities for future investigation in combination regimens, which could further expand its clinical utility. Long-term follow-up data from the ongoing trials will be crucial for confirming the durability of responses and establishing the overall survival benefit, which will ultimately define its value to patients and clinicians.

Conclusion and Expert Recommendations

The comprehensive body of evidence on KL-590586 (A400/EP0031) strongly supports its characterization as a highly promising, next-generation selective RET inhibitor with a differentiated and compelling clinical profile. The agent has been rationally designed and clinically validated to address the most pressing unmet needs in the treatment of RET-altered malignancies.

The analysis concludes that KL-590586 possesses three core strategic advantages:

1. Potent Efficacy Against Resistance: It has demonstrated clear clinical activity in patients who have progressed on first-generation SRIs, positioning it as a critical second-line therapy.
2. Robust Intracranial Activity: It has shown profound and durable responses in patients with CNS metastases, a frequent and difficult-to-treat complication.
3. Favorable Safety Profile: Its low incidence of cardiovascular and hematological toxicities common to its predecessors suggests a superior therapeutic window, better patient tolerability, and broader applicability.

Based on the strength and consistency of the preclinical and clinical data available, KL-590586 has a high probability of becoming a new standard of care for multiple segments of the RET-altered cancer population. It is poised to challenge for a best-in-class position in the first-line setting and to become the definitive treatment for patients with CNS disease or acquired resistance.

Recommendations for Future Development and Assessment:

• Pivotal Data Readout: The top-line results from the global pivotal Phase 2 study (NCT05443126) will be a critical near-term catalyst. These data will be essential for validating the findings from the Chinese KL400-I/II-01 study and supporting regulatory filings with the FDA and EMA.
• Comparative Evidence Generation: While head-to-head randomized trials are unlikely, the developers should prioritize generating robust comparative evidence through matching-adjusted indirect comparisons or real-world evidence studies to solidify claims of superiority for formulary access and clinical guideline inclusion.
• Combination Strategies: Given the manageable safety profile, a high priority should be placed on initiating clinical studies evaluating KL-590586 in combination with other systemic therapies (e.g., chemotherapy, immunotherapy, or other targeted agents) to explore potential synergies and further improve outcomes.
• Long-Term Follow-Up: Continued long-term follow-up of patients in the ongoing pivotal trials is essential to fully characterize the durability of response and to mature overall survival data, which will be the ultimate measures of the drug's clinical value.

Works cited

1. Kelun-Biotech and Ellipses A400 (EP0031) Cleared to Start Ph2 Clinical Development by US FDA - KLUS Pharma, accessed October 1, 2025, https://www.kluspharma.com/news/kelun-biotech-and-ellipses-a400-(ep0031)-cleared-to-start-ph2-clinical-development-by-us-fda
2. Ellipses Pharma presents 'encouraging' data on selective RET inhibitors, accessed October 1, 2025, https://happylungsproject.org/ellipses-pharma-presents-encouraging-data-on-next-generation-selective-ret-inhibitor-ep0031-at-asco-2023-annual-conference/
3. A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. - ASCO Publications, accessed October 1, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3007
4. A phase I study of KL590586, a next-generation selective RET ..., accessed October 1, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT415116
5. A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. | Request PDF - ResearchGate, accessed October 1, 2025, https://www.researchgate.net/publication/371295969_A_phase_I_study_of_KL590586_a_next-generation_selective_RET_inhibitor_in_patients_with_RET-altered_solid_tumors
6. A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC, accessed October 1, 2025, https://www.onclive.com/view/a400-ep0031-nda-accepted-for-review-in-china-for-ret-fusion-positive-nsclc
7. Kelun-Biotech's Next-Generation RET Inhibitor A400/EP0031 Receives NDA Acceptance in China for NSCLC Treatment - MedPath, accessed October 1, 2025, https://trial.medpath.com/news/1c1e7407aae29e0c/kelun-biotech-s-next-generation-ret-inhibitor-a400-ep0031-receives-nda-acceptance-in-china-for-nsclc-treatment
8. Adverse event profile differences between pralsetinib and ... - Frontiers, accessed October 1, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1424980/full
9. Precision therapy for RET-altered cancers with RET inhibitors - PMC - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8599646/
10. Kelun-Biotech Announced that A400/EP0031 has been granted Orphan Drug Designation by FDA - KLUS Pharma, accessed October 1, 2025, https://www.kluspharma.com/news/kelun-biotech-announced-that-a400%2Fep0031-has-been-granted-orphan-drug-designation-by-fda-
11. Newsroom - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., accessed October 1, 2025, https://en.kelun-biotech.com/newsCenter.aspx?mid=18&page=7
12. Retsevmo (selpercatinib) vs Gavreto (pralsetinib) - Everyone.org, accessed October 1, 2025, https://everyone.org/explore/compare?id1=383&id2=384
13. Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer - PMC - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12150609/
14. Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions, accessed October 1, 2025, https://www.theoncologynurse.com/lung-cancer-mm/18461:pralsetinib-and-selpercatinib-for-nsclc-patients-with-ret-gene-fusions
15. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies - PubMed, accessed October 1, 2025, https://pubmed.ncbi.nlm.nih.gov/31988000/
16. Definition of RET kinase inhibitor KL590586 - NCI Drug Dictionary ..., accessed October 1, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ret-inhibitor-kl590586
17. Kelun and Ellipses Announce a Licensing Agreement for A400, accessed October 1, 2025, https://ellipses.life/kelun-and-ellipses-announce-a-licensing-agreement-for-a400/
18. Newsroom - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., accessed October 1, 2025, https://en.kelun-biotech.com/newsCenter.aspx?mid=18&sv=A400/EP0031%20
19. Technology & Product Pipeline - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., accessed October 1, 2025, https://en.kelun-biotech.com/product.aspx?mid=165
20. A Study of KL590586 in Patients With Advanced Solid Tumors - larvol clin, accessed October 1, 2025, https://clin.larvol.com/trial-detail/NCT05265091
21. Ellipses' new RET inhibitor EP0031/A400 approved for Phase 2 - Patsnap Synapse, accessed October 1, 2025, https://synapse.patsnap.com/article/ellipses-new-ret-inhibitor-ep0031a400-approved-for-phase-2
22. Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting USA - PR Newswire, accessed October 1, 2025, https://www.prnewswire.com/news-releases/six-abstracts-of-kelun-biotechs-clinical-studies-published-at-the-2025-asco-annual-meeting-302464139.html
23. Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer. | Journal of Clinical Oncology - ASCO Publications, accessed October 1, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6098
24. A major difference in RET inhibition found between pralsetinib and selpercatinib, accessed October 1, 2025, https://communities.springernature.com/posts/a-major-difference-in-ret-inhibition-found-between-pralsetinib-and-selpercatinib
25. Occurrence and Management of Selpercatinib- and Pralsetinib-Related AEs in Patients with RET Fusion-Positive mNSCLC | Targeted Oncology, accessed October 1, 2025, https://www.targetedonc.com/view/occurrence-and-management-of-selpercatinib--and-pralsetinib-related-aes-in-patients-with-ret-fusion-positive-mnsclc